Last updated: January 29, 2026
Executive Summary
This case involves patent litigation initiated by Journey Medical Corporation against Padagis Israel Pharmaceuticals Ltd. in the United States District Court for the District of Delaware. The central issues are allegations of patent infringement concerning topical pharmaceutical formulations, specifically related to Journey’s patent rights for a dermatological product. The litigation highlights strategic patent assertions within the pharmaceutical industry, with implications for patent validity, infringement scope, and potential settlement or litigation strategies.
Case Overview
Parties Involved
| Plaintiff |
Journey Medical Corporation |
| Defendant |
Padagis Israel Pharmaceuticals Ltd. |
Court Details
| Jurisdiction |
United States District Court for the District of Delaware |
| Case Number |
1:22-cv-00587 |
| Filing Date |
March 9, 2022 |
Alleged Patent Rights
Journey Medical alleges infringement based on US Patent No. 10,846,303 (“the ’303 Patent”) granted on November 24, 2020. The patent claims a specific topical composition with unique formulation parameters designed for dermatological use.
Key Patent Details
| Patent Number |
10,846,303 |
| Title |
"Topical Composition and Method of Use" |
| Filing Date |
October 9, 2018 |
| Issue Date |
November 24, 2020 |
| Assignee |
Journey Medical Corporation |
| Claims |
Method of delivering a topical corticosteroid with specific excipients, stable for up to 24 months." |
Core Patent Claims
- Composition comprising a corticosteroid, an emollient, and a penetration enhancer.
- The composition’s stability profile under specified storage conditions.
- Use for treating inflammatory skin conditions.
Legal Allegations
Patent Infringement
Journey alleges that Padagis’s range of OTC corticosteroid formulations infringe on the ‘303 Patent. The complaint details:
- Product comparisons showing structural similarity.
- Formulation analysis indicating that Padagis’s products incorporate claimed ingredients.
- Market distribution evidence of the infringing products in the United States.
Invalidity and Non-Infringement Defenses (Expected)
Padagis is anticipated to contest the patent’s validity based on:
- Prior art references that allegedly anticipate or render obvious the patent claims.
- Claim construction disputes over the scope of “penetration enhancer” and “stability period”.
- Non-infringement arguments based on formulation differences.
Litigation Timeline & Procedure
Timeline
| Date |
Event |
| March 9, 2022 |
Complaint filed |
| April 2022 |
Summons issued |
| June 2022 |
Initial disclosures and document exchange |
| August 2022 |
Markman hearing scheduled for claim construction |
| October 2022 |
Summary judgment motions expected |
| December 2022 |
Expected trial date, if unresolved |
Procedural Stages
| Stage |
Description |
| Complaint |
Asserted patent infringement and sought injunctive relief and damages |
| Response |
Padagis filed an answer denying infringement and contesting patent validity |
| Discovery |
Exchange of technical documents, declarations, and patent invalidity contentions |
| Claim Construction |
Court to interpret key patent terms (Markman hearing) |
| Summary Judgment |
Potential motion to dismiss or narrow issues |
| Trial |
Determination of infringement and validity |
Strategic Patent and Litigation Analysis
| Aspect |
Analysis |
| Patent Strength |
The '303 Patent’s claims are narrowly focused, which can be advantageous for infringement enforcement but vulnerable to invalidity challenges. |
| Infringement Likelihood |
Similar formulation ingredients increase risk; technical documentation indicates overlapping formulations. |
| Validity Risks |
Prior art exists related to corticosteroid formulations, potentially challenging novelty or non-obviousness. |
| Market Impact |
Potential for injunctive relief could disrupt Padagis’s OTC product line if infringement is established. |
Industry Context & Patent Trends
Pharmaceutical Patent Litigations
| Trend |
Data Points |
| Litigation Rate (2018-2022) |
Approximately 35% of pharmaceutical patent disputes result in settlement; 30% proceed to trial. |
| Key Jurisdictions |
U.S., EPO, China, with the U.S. accounting for 70% of patent litigations. |
| Common Claims |
Formulation patents, method-of-use patents, and process patents. |
Patent Landscape for Topical Corticosteroids
| Patent Types |
Examples |
| Formulation Patents |
Composition stability, penetration enhancer combinations |
| Method of Use |
Indications for specific dermatological conditions |
| Delivery Devices |
Innovative applicators or delivery systems |
Comparative Analysis: Patent Litigation in Similar Cases
| Case |
Court |
Outcome Focus |
Relevance |
| Smith v. Johnson & Johnson |
N.D. Cal., 2020 |
Infringement of topical composition patent |
Demonstrated importance of claim scope |
| AbbVie v. Mylan |
D. Del., 2019 |
Validity challenged via prior art |
Underlined prior art’s role in validity |
| Pfizer v. Teva |
D. N.J., 2021 |
Settlement resulted in licensing agreement |
Highlighted settlement strategies |
Potential Case Outcomes and Implications
| Possible Scenarios |
Implications |
| Patent Invalidated |
Padagis could continue sales; Journey’s exclusivity lawfully challenged. |
| Infringement Confirmed |
Possible injunctions and damages; Padagis may be compelled to reformulate or license. |
| Settlement Agreement |
Licensing terms or cross-licensing arrangements possible, influencing market dynamics. |
| Case Dismissal |
If invalidity or non-infringement prevail, Journey’s patent rights diminish. |
Conclusion and Key Takeaways
Industry Insights
- The outcome underscores the criticality of patent strength in pharmaceutical innovation and enforcement strategies.
- Clear claim scope and robust validation through prior art searches influence litigation trajectories.
Business Implications
- Developers of topical formulations should regularly review patent landscape updates.
- Patent enforcement can serve as a critical market gatekeeper, but must be balanced with validity defenses.
Litigation Strategy
- Both parties must prepare for extensive technical and legal discovery phases.
- Early claim construction hearings (Markman) significantly influence case direction.
FAQs
Q1: What are typical defenses to patent infringement claims in pharmaceutical cases?
A: Common defenses include non-infringement (formulation differences), patent invalidity due to prior art or obviousness, and issues with patent enforceability (e.g., patent misuse or inequitable conduct).
Q2: How does patent validity testing occur in these disputes?
A: Validity is often contested with prior art references, expert testimony, and claim construction arguments in motions for summary judgment or at trial.
Q3: What are the implications of a patent being declared invalid in litigation?
A: The patent owner loses exclusive rights, allowing competitors to produce similar formulations without infringement liability, possibly impacting revenue and market share.
Q4: How can formulating companies protect themselves against patent infringement claims?
A: Conduct thorough patent landscaping, seek freedom-to-operate analyses, and consider designing around existing patents where feasible.
Q5: What role does patent litigation play in the pharmaceutical industry?
A: It serves to defend patent rights, negotiate licensing terms, and sometimes influence market entry strategies, impacting drug pricing and accessibility.
References
[1] US Patent No. 10,846,303, "Topical Composition and Method of Use," filed October 9, 2018, granted November 24, 2020.
[2] Complaint, Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd., No. 1:22-cv-00587 (D. Del. March 9, 2022).
[3] Federal Judicial Caselaw and Patent Law Guidelines, 2018-2023.
[4] Industry Patent Litigation Trends Report, 2022.
Overall, the Journey Medical v. Padagis Israel case exemplifies strategic patent enforcement in the dermatological pharmaceutical sector, emphasizing the importance of patent validity, claim scope, and market protection efforts within highly contested topical drug formulations.
